Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cairo Univ. EGFR/VEGFR2 compound 3e: sourced facts only. name: "Compound 3e was the most potent against EGFR and VEGFR2 with IC50 values of 0.142 and 0.071 μM compared to erlotinib and axitinib with IC50 values of 0.064 and 0.050 μM, respectively."; target: "Compound 3e was the most potent against EGFR and VEGFR2 with IC50 values of 0.142 and 0.071 μM compared to erlotinib and axitinib with IC50 values of 0.064 and 0.050 μM, respectively."; target: "Compound 3e was the most potent against EGFR and VEGFR2 with IC50 values of 0.142 and 0.071 μM compared to erlotinib and axitinib with IC50 values of 0.064 and 0.050 μM, respectively."; developer: "Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, 11562 Cairo, Egypt."; stage: "Boyden chamber and wound healing assays demonstrated that compound 3e could impair cell migration and invasion in T47D cells."
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cairo Univ. EGFR/VEGFR2 compound 3e.
Work on Cairo Univ. EGFR/VEGFR2 compound 3e? Claim this page to correct or add information. Claim this page